POLA PENGGUNAAN OBAT ANTIRETROVIRAL (ARV) PADA RESEP PASIEN RAWAT JALAN DARI KLINIK HIV/AIDS SALAH SATU RUMAH SAKIT SWASTA DI KOTA BANDUNG
DOI:
https://doi.org/10.33759/jrki.v1i1.10Keywords:
Antiretroviral, HIV/AIDS, Pattern of Drug UseAbstract
ABSTRACT
The Human Immunodeficiency Virus (HIV) continues to be a major global public health issue, which targets the human immune system. The using of ARVs in the treatment of HIV / AIDS increased life expectancy for PLHIV (People With HIV / AIDS). This study aims to determine the description of the using of ARV drugs in outpatients of the HIV / AIDS Clinic and assessed their suitability with established treatment standards. This research was carried out in a descriptive non-experimental manner, with data collection carried out retrospectively, used patient prescription data from April to December 2017. The results of quantitative studies showed 87% were male patients, and the largest age group was 20-29 years (39%) . Class of antiretroviral drugs used were Nucleoside / Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), and Protease Inhibitors (PI), with a combination of antiretroviral drugs most was the combination of first-line tenofovir + lamivudine + efavirenz (69%) while the second-line drug zidovudine + lamivudine + lopinavir / ritonavir was 1%. The most commonly used comorbid drug was cotrimoxazole. For qualitative data, the accuracy of combination and dose of ARV drugs was 100% in accordance with Permenkes No. 87/ 2014, with 79% of patients adhered to antiretroviral treatment every month. The potential for most ARV drug interactions with other drugs for the moderate category was zidovudin + cotrimoxazole (11%) which occured pharmacokinetically by decreasing renal clearance of zidovudine and glucuronide metabolites. In conclusion, the pattern of used of ARV drugs had met the standard of Permenkes No.87/2014, with the most used were the first line combination of tenofovir + lamivudine + efavirenz.
Downloads
References
Ditjen P2P Kemenkes RI (2016) : Laporan Perkembangan HIV-AIDS dan Penyakit Infeksi Menular Seksual (PIMS) Triwulan III Tahun 2016, Kementerian Kesehatan RI, Jakarta.
Ditjen P2P Kemenkes RI (2017) : Laporan Perkembangan HIV-AIDS dan Penyakit Infeksi Menular Seksual (PIMS) Triwulan I Tahun 2017, Kementerian Kesehatan RI, Jakarta.
Jamil, K.F (2014) : Profil Kadar CD4 terhadap Infeksi Oportunistik pada Penderita Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome (HIV/AIDS) di RSUD DR.Zainoel Abidin Banda Aceh, Jurnal Kedokteran Syiah Kuala, 14(2), 79.
Katzung, B.G. dan Trevor, A.J. (2015) : Basic and Clinical Pharmacology, Thirteenth Edition, McGraw-Hill Education, New York, 1244-1257.
Kusumayanti, R.R., Yunihastuti, E., Purnamasari, D., Witjaksono, F., dan Dewiasty E. (2015) : Faktor-Faktor yang Berperan terhadap Terjadinya Lipodistrofi pada Pasien HIV yang Mendapatkan Terapi Antiretroviral Lini Pertama, Jurnal Penyakit Dalam Indonesia, 2 , 223.
Menteri Kesehatan RI (2014) : peraturan Menteri Kesehatan Republik Indonesia Nomor 87 Tahun 2014 tentang Pedoman Pengobatan Antiretroviral, Kementerian Kesehatan RI, Jakarta, 7-65.
Pusdatin Kemenkes RI (2016) : Situasi Penyakit HIV AIDS di Indonesia, Kementerian Kesehatan RI, Jakarta, 1-
Siregar, C.J.P. dan Kumolosasi. E. (2006) : Farmasi Klinik : Teori dan Terapan, Cetakan I, Penerbit Buku Kedokteran EGC, Jakarta, 306-307.
Surilena dan Valeri J.(2015) : Knowledge of HIV-AIDS a dominant factor of antiretroviral theraupetic adherence in women with HIV-AIDS, Universa Medicina, 34(2), 129.
Tatro, D. (2014) : Drug Interaction Facts, Facts and Comparison Publishing Group, California, xiii-xvii, 249, 299, 1408, 1125, 2170, 2180.
WHO (2016) : Consolidated Guidelines on The Use of Antiretroviral Drugs for Treating and Preventing HIV infection, 2nd Edition, WHO Press, Switzerland, 388-395.
WHO (2017) : Elimination of Mother- to-Child Transmission of HIV (EMTCT), http://www.who.int /mediacentre / factsheets /fs360/en/, diakses tanggal 13 Maret 2018.
WHO (2017) : HIV/AIDS Key Facts, http://www.who.int/ mediacentre/factsheets/ fs360 /en/, diakses tanggal 11 Oktober 2017.
WHO (2017) : HIV Drug Resistance, http://www.who.int/hiv/topics /drugresistance/en/, diakses tanggal 11Oktober 2017.
Widiyanti, M., Sandy, S., Fitriana, E. (2015) : Dampak Perpaduan Obat ARV pada pasien HIV/AIDS ditinjau dari kenaikan Jumlah Limfosit CD4+ di RSUD Dok II Kota Jayapura, PLASMA, 1(2), 53-58.
Downloads
Published
Issue
Section
License
Articles published in The Jurnal Riset Kefarmasian Indonesia (JRKI) are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0).
This license permits users to copy, redistribute, share, translate, adapt, and build upon the published material for non-commercial purposes, provided that appropriate credit is given to the original author(s) and the journal, a link to the license is provided, and any changes made are clearly indicated.
If users remix, transform, or build upon the material, they must distribute their contributions under the same license or a license permitted by the applicable ShareAlike terms.
The material may not be used for commercial purposes under this license without additional permission from the relevant copyright holder.
Authors retain copyright of their published works and grant The Jurnal Riset Kefarmasian Indonesia the right of first publication.
Full license terms are available at: https://creativecommons.org/licenses/by-nc-sa/4.0/
